SLC5A2 and urinary tract infection: The study included about 7400 participants and the results demonstrated that the use of SGLT2 inhibitors did not increase the risk of urinary tract infections or their recurrence compared to other non-insulin medications; moreover, the risk of urinary tract infections was lower compared to insulin [33].